SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Dynavax DVAX
DVAX 10.24+1.8%Nov 5 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LJM who wrote (37)10/19/2006 9:05:17 PM
From: LJM   of 184
 
Dynavax shares surge on news of flu vaccine

8:10pm 10/19/2006

DVAX6.13, -0.42, -6.4%) shares surged 5% in after-hours trade Thursday after the Berkeley, Calif.-based company said new preclinical data shows its flu vaccine can improve the immunogenicity of standard flu vaccines. The company will present the data tomorrow at the Second International Conference on Influenza Vaccines for the World in Vienna, Austria. Dynavax said in a statement that the data, from mouse and primate models, demonstrate that co-administration of its flu vaccine with standard vaccines "enhances the immune response of the standard vaccine, allows reduction of standard vaccine dosage, and provides extra layers of protection that are not strain-dependent." "Our findings in flu give us confidence about our ability to move forward quickly with a commercial product," said Gary Van Nest, the company's vice president of preclinical research.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext